XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2024
Revenue Recognition  
Schedule of disaggregation of revenues by payer types

​

​

​

​

​

​

​

​

​

​

​

Three months ended

​

​

​

March 31, 

​

​

​

2024

​

2023

​

​

​

(in thousands)

​

Insurance carriers

​

$

341,028

​

$

210,378

​

Laboratory and other partners

​

​

20,276

​

​

22,805

​

Patients

​

​

6,437

​

​

8,573

​

Total revenues

​

$

367,741

​

$

241,756

​

Schedule of total revenue by geographic area

​

​

​

​

​

​

​

​

​

​

Three months ended

​

​

March 31, 

​

    

2024

    

2023

​

​

(in thousands)

United States

 

$

359,413

​

$

233,254

Americas, excluding U.S.

 

​

1,481

​

​

1,158

Europe, Middle East, India, Africa

 

​

5,178

​

​

5,196

Asia Pacific and Other

 

​

1,669

​

​

2,148

Total revenues

 

$

367,741

​

$

241,756

Schedule of beginning and ending balances of accounts receivable and deferred revenues

​

​

​

​

​

​

​

​

​

​

Balance at

​

​

March 31, 

​

December 31,

​

​

2024

​

2023

​

​

(in thousands)

Assets:

​

​

​

​

​

​

Accounts receivable, net

​

$

288,748

​

$

278,289

Liabilities:

​

​

​

​

​

​

Deferred revenue, current portion

​

$

17,705

​

$

16,612

Deferred revenue, long-term portion

​

​

18,828

​

​

19,128

Total deferred revenues

​

$

36,533

​

$

35,740

Schedule of changes in the balance of deferred revenues

​

​

​

​

​

​

​

​

​

​

March 31, 

​

​

2024

​

​

2023

​

(in thousands)

Beginning balance

​

$

35,740

​

$

30,778

Increase in deferred revenues

​

​

7,941

​

​

12,100

Revenue recognized during the period that was included in deferred revenues at the beginning of the period

​

​

(7,048)

​

​

(3,988)

Revenue recognized from performance obligations satisfied within the same period

​

​

(100)

​

​

(800)

Ending balance

​

$

36,533

​

$

38,090